Published in MAbs on May 01, 2011
Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol (2012) 2.45
Structural analysis of B-cell epitopes in antibody:protein complexes. Mol Immunol (2012) 1.28
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med (2012) 1.14
Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One (2013) 1.03
Characterization and screening of IgG binding to the neonatal Fc receptor. MAbs (2014) 0.93
Molecular engineering of antibodies for therapeutic and diagnostic purposes. MAbs (2012) 0.87
Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG. J Virol (2013) 0.85
Anti-cadherin-17 antibody modulates beta-catenin signaling and tumorigenicity of hepatocellular carcinoma. PLoS One (2013) 0.84
Antibody engineering for increased potency, breadth and half-life. Curr Opin HIV AIDS (2015) 0.83
Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life. MAbs (2015) 0.83
Bridging the gap: facilities and technologies for development of early stage therapeutic mAb candidates. MAbs (2011) 0.83
Aggregates, crystals, gels, and amyloids: intracellular and extracellular phenotypes at the crossroads of immunoglobulin physicochemical property and cell physiology. Int J Cell Biol (2013) 0.83
Pharmacokinetic mAb-mAb interaction: anti-VEGF mAb decreases the distribution of anti-CEA mAb into colorectal tumor xenografts. AAPS J (2012) 0.82
Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies. J Toxicol Pathol (2015) 0.82
Thermodynamic stability and flexibility characteristics of antibody fragment complexes. Protein Pept Lett (2014) 0.82
A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. MAbs (2015) 0.81
Non-antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity. MAbs (2015) 0.79
Tau Immunotherapy. Neurodegener Dis (2015) 0.78
Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys. MAbs (2016) 0.77
Oxidation in the complementarity-determining regions differentially influences the properties of therapeutic antibodies. MAbs (2016) 0.77
Antibody Derived Peptides for Detection of Ebola Virus Glycoprotein. PLoS One (2015) 0.75
Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach. MAbs (2015) 0.75
CHO cell production and sequence improvement in the 13C6FR1 anti-Ebola antibody. MAbs (2016) 0.75
Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies. Front Immunol (2016) 0.75
Eliminating antibody polyreactivity through addition of N-linked glycosylation. Protein Sci (2015) 0.75
Advanced assessment of the physicochemical characteristics of Remicade® and Inflectra® by sensitive LC/MS techniques. MAbs (2016) 0.75
Molecular Insights into Fully Human and Humanized Monoclonal Antibodies: What are the Differences and Should Dermatologists Care? J Clin Aesthet Dermatol (2016) 0.75
Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds. Front Immunol (2017) 0.75
Affinity Maturation of Monoclonal Antibody 1E11 by Targeted Randomization in CDR3 Regions Optimizes Therapeutic Antibody Targeting of HER2-Positive Gastric Cancer. PLoS One (2015) 0.75
Emerging Diagnostic and Therapeutic Strategies for Tauopathies. Curr Neurol Neurosci Rep (2017) 0.75
Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody. MAbs (2017) 0.75
Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol (2010) 6.04
Effects of protein aggregates: an immunologic perspective. AAPS J (2006) 4.74
Selecting and screening recombinant antibody libraries. Nat Biotechnol (2005) 4.51
Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci (2004) 4.28
Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol (2010) 4.21
Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature (1986) 4.19
Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science (2009) 3.87
Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci U S A (2000) 3.77
Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. Immunity (1998) 3.27
Computational design of antibody-affinity improvement beyond in vivo maturation. Nat Biotechnol (2007) 2.92
High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res (2001) 2.90
Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol (2002) 2.77
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis (2007) 2.67
Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol (2006) 2.66
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem (2006) 2.58
Challenges in the development of high protein concentration formulations. J Pharm Sci (2004) 2.52
Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood (2008) 2.50
Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol (2007) 2.45
Kinetic and affinity limits on antibodies produced during immune responses. Proc Natl Acad Sci U S A (1995) 2.41
Immunogenicity of engineered antibodies. Methods (2005) 2.41
Enhanced antibody half-life improves in vivo activity. Nat Biotechnol (2010) 2.33
Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm (2005) 2.26
Antibody structure, instability, and formulation. J Pharm Sci (2007) 2.25
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis (2008) 2.21
Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today (2006) 2.21
Human antibodies from transgenic animals. Nat Biotechnol (2005) 2.04
Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res (1997) 1.91
Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J Mol Biol (2005) 1.90
Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J Mol Biol (1996) 1.90
CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol (1995) 1.90
Molecular clocks. Proc Natl Acad Sci U S A (2001) 1.88
An engineered human IgG1 antibody with longer serum half-life. J Immunol (2006) 1.88
Heterogeneity of monoclonal antibodies. J Pharm Sci (2008) 1.87
The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs (2010) 1.86
Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol (1999) 1.85
Biophysical properties of human antibody variable domains. J Mol Biol (2003) 1.80
Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries. Proc Natl Acad Sci U S A (1998) 1.69
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol (2010) 1.66
Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat Biotechnol (2000) 1.65
Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel (2010) 1.64
Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design. Protein Sci (2006) 1.55
Minimizing the immunogenicity of protein therapeutics. Drug Discov Today (2004) 1.52
Process economics of industrial monoclonal antibody manufacture. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.50
The carbohydrate contents of fragments and polypeptide chains of human gamma-G-myeloma proteins of different heavy-chain subclasses. Biochemistry (1968) 1.49
Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J (2009) 1.48
A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem Biophys Res Commun (2007) 1.46
Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. Methods (2004) 1.37
A general method for greatly improving the affinity of antibodies by using combinatorial libraries. Proc Natl Acad Sci U S A (2005) 1.37
Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int (2006) 1.36
Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. MAbs (2009) 1.33
Mammalian meat-induced anaphylaxis: clinical relevance of anti-galactose-alpha-1,3-galactose IgE confirmed by means of skin tests to cetuximab. J Allergy Clin Immunol (2009) 1.33
Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol (2007) 1.33
Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity. J Pharm Sci (2008) 1.32
Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol (2007) 1.32
Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Anal Biochem (2009) 1.31
Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. MAbs (2009) 1.30
Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol (2009) 1.30
Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel (2010) 1.27
Tailoring in vitro evolution for protein affinity or stability. Proc Natl Acad Sci U S A (2001) 1.26
A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. J Infect Dis (1999) 1.24
Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol (2008) 1.24
Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods (1999) 1.23
Human immune response to recombinant human proteins. J Pharm Sci (2001) 1.23
Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng Des Sel (2010) 1.21
Prediction of immunogenicity of therapeutic proteins: validity of computational tools. BioDrugs (2010) 1.17
Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol (1996) 1.17
Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol (2008) 1.16
Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther (2008) 1.14
Antibody affinity maturation using bacterial surface display. Protein Eng (1998) 1.13
In vitro evolution of single-chain antibodies using mRNA display. Nucleic Acids Res (2006) 1.11
How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev (2008) 1.11
Cryoglobulinemia. Blood Rev (2007) 1.11
Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies. J Pharm Sci (2010) 1.09
Antibody variable region glycosylation: position effects on antigen binding and carbohydrate structure. EMBO J (1991) 1.09
Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res (2001) 1.09
Affinity maturation of antibodies assisted by in silico modeling. Proc Natl Acad Sci U S A (2008) 1.09
Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody. AAPS J (2008) 1.09
Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther (2003) 1.07
Glutamine-linked and non-consensus asparagine-linked oligosaccharides present in human recombinant antibodies define novel protein glycosylation motifs. J Biol Chem (2010) 1.04
Ribosome display: an in vitro method for selection and evolution of antibodies from libraries. J Immunol Methods (1999) 1.04
Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization. Anticancer Drugs (2010) 1.04
Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: identification and effect on binding affinity. Biochemistry (1996) 1.03
Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Sci (2010) 1.02
The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res (1992) 1.02
T cell epitope: friend or foe? Immunogenicity of biologics in context. Adv Drug Deliv Rev (2009) 1.02
Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer. Clin Cancer Res (2003) 1.02
High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. Ann Rheum Dis (2006) 1.01
Increased aggregation propensity of IgG2 subclass over IgG1: role of conformational changes and covalent character in isolated aggregates. Protein Sci (2010) 1.00
Use of human germline genes in a CDR homology-based approach to antibody humanization. Methods (2005) 1.00
Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain. J Pharm Sci (2009) 1.00
New approaches to prediction of immune responses to therapeutic proteins during preclinical development. Drugs R D (2008) 0.99
"Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28. J Immunol (2002) 0.98
Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol (2008) 0.98
De novo selection of high-affinity antibodies from synthetic fab libraries displayed on phage as pIX fusion proteins. J Mol Biol (2010) 0.97
Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem (2010) 0.97
Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol (Basel) (2003) 0.95
Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Devel (2007) 0.95
Identification of a single tryptophan residue as critical for binding activity in a humanized monoclonal antibody against respiratory syncytial virus. Anal Chem (2007) 0.95
Removal of cysteinylation from an unpaired sulfhydryl in the variable region of a recombinant monoclonal IgG1 antibody improves homogeneity, stability, and biological activity. J Pharm Sci (2008) 0.94
The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains. Protein Eng Des Sel (2009) 0.93
Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res (2004) 2.34
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol (2010) 1.66
Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res (2008) 1.35
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med (2012) 1.14
Reporter expression, induced by a growth hormone promoter-driven Cre recombinase (rGHp-Cre) transgene, questions the developmental relationship between somatotropes and lactotropes in the adult mouse pituitary gland. Endocrinology (2007) 1.09
Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization. Anticancer Drugs (2010) 1.04
Effects of insulin, leptin, and glucagon on ghrelin secretion from isolated perfused rat stomach. Regul Pept (2004) 1.04
Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One (2013) 1.03
Ghrelin stimulates GH but not food intake in arcuate nucleus ablated rats. Endocrinology (2002) 1.01
Engineered monoclonal antibody with novel antigen-sweeping activity in vivo. PLoS One (2013) 0.99
A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment. Cancer Res (2007) 0.96
A new method for isolating colonocytes from naturally evacuated feces and its clinical application to colorectal cancer diagnosis. Gastroenterology (2005) 0.91
Recombinant human hexamer-dominant IgM monoclonal antibody to ganglioside GM3 for treatment of melanoma. Clin Cancer Res (2007) 0.90
A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood (2004) 0.90
Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant. MAbs (2013) 0.86
VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody. Protein Eng Des Sel (2010) 0.85
Prevalence of dementia in Japan: a systematic review. Dement Geriatr Cogn Disord (2013) 0.85
The estrogen receptor (ER) alpha, but not ER beta, gene is expressed in hypothalamic growth hormone-releasing hormone neurons of the adult female rat. Neurosci Res (2005) 0.84
Novel genetically-humanized mouse model established to evaluate efficacy of therapeutic agents to human interleukin-6 receptor. Sci Rep (2013) 0.83
Factor VIII contributes to platelet-fibrin thrombus formation via thrombin generation under low shear conditions. Thromb Res (2009) 0.82
Crystal structure of human factor VIIa/tissue factor in complex with peptide mimetic inhibitor. Biochem Biophys Res Commun (2004) 0.81
Microchip electrophoresis of tagged probes incorporated with one-colored ddNTP for analyzing single-nucleotide polymorphisms. Anal Chem (2003) 0.81
The role of pituitary ghrelin in growth hormone (GH) secretion: GH-releasing hormone-dependent regulation of pituitary ghrelin gene expression and peptide content. Endocrinology (2004) 0.80
In vitro evaluation of blood coagulation activation and microthrombus formation by a microchannel array flow analyzer. Thromb Res (2004) 0.80
Predicting the timeline to the final menstrual period: the study of women's health across the nation. J Clin Endocrinol Metab (2013) 0.80
Insulin-like growth factor-I down-regulates ghrelin receptor (growth hormone secretagogue receptor) expression in the rat pituitary. Regul Pept (2005) 0.79
Non-antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity. MAbs (2015) 0.79
Non-biased and efficient global amplification of a single-cell cDNA library. Nucleic Acids Res (2013) 0.78
The effect of agouti-related protein on growth hormone secretion in adult male rats. Regul Pept (2005) 0.78
Association of serum apolipoprotein B48 level with the presence of carotid plaque in type 2 diabetes mellitus. Diabetes Res Clin Pract (2008) 0.78
Increased CD45RO+ CD62L+ CD4+ T-cell subpopulation responsible for Th2 response in Kimura's disease. Hum Immunol (2013) 0.78
Reversal of antigen-dependent signaling by two mutations in antibody/receptor chimera: implication of inverse agonism in cytokine receptor superfamily. Biochem Pharmacol (2004) 0.78
Structure of human factor VIIa/tissue factor in complex with a peptide-mimetic inhibitor: high selectivity against thrombin by introducing two charged groups in P2 and P4. Acta Crystallogr Sect F Struct Biol Cryst Commun (2005) 0.77
Factor VIIa inhibitors: target hopping in the serine protease family using X-ray structure determination. Bioorg Med Chem Lett (2008) 0.77
Priorities of health care outcomes for the elderly. J Am Med Dir Assoc (2013) 0.77
Fc Engineering to Improve the Function of Therapeutic Antibodies. Curr Pharm Biotechnol (2016) 0.76
Elevated plasma factor VIII enhances venous thrombus formation in rabbits: contribution of factor XI, von Willebrand factor and tissue factor. Thromb Haemost (2013) 0.76
Mutant firefly luciferases with improved specific activity and dATP discrimination constructed by yeast cell surface engineering. Appl Microbiol Biotechnol (2012) 0.76
Inhibition of factor XI reduces thrombus formation in rabbit jugular vein under endothelial denudation and/or blood stasis. Thromb Res (2010) 0.76
Effective screening method of agonistic diabodies based on autocrine growth. J Immunol Methods (2009) 0.76
Design and synthesis of peptidomimetic factor VIIa inhibitors. Chem Pharm Bull (Tokyo) (2010) 0.75
Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost (2017) 0.75
Total-reflection active-mirror laser with cryogenic Yb:YAG ceramics. Opt Lett (2009) 0.75
Boiling effect in liquid nitrogen directly cooled Yb<sup>3+</sup>:YAG laser. Appl Opt (2016) 0.75
Cutoff value of thyroid uptake of (99m)Tc-pertechnetate to discriminate between Graves' disease and painless thyroiditis: a single center retrospective study. Endocr J (2015) 0.75
Characterisation of an antibody specific for coagulation factor VIII that enhances factor VIII activity. Thromb Haemost (2009) 0.75
Chylomicronemia caused by lipoprotein lipase gene mutation related to a hyper-response of insulin secretion to glucose. Intern Med (2002) 0.75
Zig-zag active-mirror laser with cryogenic Yb3+:YAG/YAG composite ceramics. Opt Express (2011) 0.75
Cardiac myocytes are recruited by bone marrow-derived cells in intact murine heart. Kobe J Med Sci (2002) 0.75
Novel interactions of large P3 moiety and small P4 moiety in the binding of the peptide mimetic factor VIIa inhibitor. Biochem Biophys Res Commun (2005) 0.75
Amplification characteristics of a cryogenic Yb³⁺:YAG total-reflection active-mirror laser. Appl Opt (2014) 0.75
Comparison of pituitary-adrenal responsiveness between insulin tolerance test and growth hormone-releasing peptide-2 test: a pilot study. Peptides (2010) 0.75
Convenient single-nucleotide polymorphism typing from whole blood by probe extension and bioluminescence detection. Clin Chem (2004) 0.75
Structure-based design of P3 moieties in the peptide mimetic factor VIIa inhibitor. Biochem Biophys Res Commun (2005) 0.75